GUCY2C

GUCY2C 詳細

英語名Heat-stable enterotoxin receptor市販薬剤の数1
治験薬の数9ターゲットの別称GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
研究&開発段階Approved
英語名Heat-stable enterotoxin receptor
ターゲットの別称GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
市販薬剤の数1
治験薬の数9
研究&開発段階Approved

GUCY2Cバックグランド

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.

GUCY2C分子の別称

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

ライセンシング

プロジェクト薬物タイプ治療分野適応症ステージエリア
Anti-GCC humanized antibodyBispecific antibodyOncology/CancerSolid TumorPreclinicalGlobal

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)Phase 1 ClinicalHeFei Parasol Biotech Co LtdColorectal Neoplasms
詳細
anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech)LCAR-G08TPhase 1 ClinicalLegend Biotech CorpColorectal Neoplasms; Gastrointestinal Neoplasms
詳細
HD-006HD006; HD-006Phase 1 ClinicalHuadao (Shanghai) Biopharma Co LtdSolid tumours
詳細
REVO-UWD-01REVO-UWD-01; WD 01Phase 1 ClinicalWondercel Therapeutics Co LtdColorectal Neoplasms
詳細
IM96 CAR-T cell TherapyIM96Phase 1 ClinicalImunopharm Technology Co LtdColorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
詳細
GCC19CARTGCC19CART; LYL273; LYL-273Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdColorectal Neoplasms; Rectal Neoplasms
詳細
Gucy2c cart cell therapy (Innovative Cellular Therapeutics)Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdDigestive System Neoplasms
詳細
XKDCT-080XKDCT-080ClinicalThe Affiliated Hospital Of Qingdao UniversityColonic Neoplasms; Solid tumours
詳細
CT-080CT-080ClinicalShenzhen Celconta Life Science Co LtdSolid tumours
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
PlecanatideSP-304; GCRAApprovedSynergy Pharmaceuticals IncTrulanceUnited StatesConstipation; Chronic idiopathic constipationSalix Pharmaceuticals2017-01-19Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8